1. Greene, J. A., & Loscalzo, J. (2017). Putting the patient back together-social medicine, network medicine, and the limits of reductionism. The New England journal of medicine, 377(25), 2493-2499.
2. Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., ... & Overington, J. P. (2017). A comprehensive map of molecular drug targets. Nature reviews Drug discovery, 16(1), 19-34.
3. Cheng, F., Hong, H., Yang, S., & Wei, Y. (2017). Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era. Briefings in bioinformatics, 18(4), 682-697.
4. Cheng, F. (2019). In silico oncology drug repositioning and polypharmacology. Cancer Bioinformatics, 243-261.
5. Zumla, A., Chan, J. F., Azhar, E. I., Hui, D. S., & Yuen, K. Y. (2016). Coronaviruses—drug discovery and therapeutic options. Nature reviews Drug discovery, 15(5), 327-347.
6. Bhoyar, R. C., Jain, A., Sehgal, P., Divakar, M. K., Sharma, D., Imran, M., ... & Sivasubbu, S. (2021). High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next-generation sequencing. PloS one, 16(2), e0247115.
7. Pandya, M., Shah, S., Menamadathil, D., Gadnayak, A., Juneja, T., Patel, A., ... & Das, J. (2021). Unravelling Vitamins as Wonder Molecules for Covid-19 Management via Structure-based Virtual Screening.
8. Wu, C., Zheng, M., Yang, Y., Gu, X., Yang, K., Li, M., ... & Li, H. (2020). Furin: a potential therapeutic target for COVID-19. Iscience, 23(10), 101642.
9. Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., ... & Pontén, F. (2015). Tissue-based map of the human proteome. Science, 347(6220).
10. Tian, S. (2009). A 20 residues motif delineates the furin cleavage site and its physical properties may influence viral fusion. Biochemistry Insights, 2, BCI-S2049.
11. Tian, S., Huang, Q., Fang, Y., & Wu, J. (2011). FurinDB: A database of 20-residue furin cleavage site motifs, substrates and their associated drugs. International journal of molecular sciences, 12(2), 1060-1065.
12. Selzer, P., & Ertl, P. (2006). Applications of self-organizing neural networks in virtual screening and diversity selection. Journal of chemical information and modeling, 46(6), 2319-2323.
13. Schneider, P., Tanrikulu, Y., & Schneider, G. (2009). Self-organizing maps in drug discovery: compound library design, scaffold-hopping, repurposing. Current medicinal chemistry, 16(3), 258-266.
14. Hristozov, D. P., Oprea, T. I., & Gasteiger, J. (2007). Virtual screening applications: a study of ligand-based methods and different structure representations in four different scenarios. Journal of computer-aided molecular design, 21(10), 617-640.
15. Xiao, Y. D., Clauset, A., Harris, R., Bayram, E., Santago, P., & Schmitt, J. D. (2005). Supervised self-organizing maps in drug discovery. 1. Robust behavior with overdetermined data sets. Journal of chemical information and modeling, 45(6), 1749-1758.
16. Levin, J. M., Oprea, T. I., Davidovich, S., Clozel, T., Overington, J. P., Vanhaelen, Q., ... & Zhavoronkov, A. (2020). Artificial intelligence, drug repurposing and peer review. Nature Biotechnology, 38(10), 1127-1131.
17. Gad, A., Manuel, A. T., Jinuraj, K. R., John, L., Sajeev, R., VG, S. P., & UC, A. J. (2017). Virtual screening and repositioning of inconclusive molecules of beta-lactamase Bioassays—A data mining approach. Computational biology and chemistry, 70, 65-88.
18. Vanommeslaeghe, K. and MacKerell Jr, A.D., ( 2012) “Automation of the CHARMM General Force Field (CGenFF) I: bond perception and atom typing”. Journal of chemical information and modeling, 52(12), pp.3144-3154
19. Jinuraj, K. R., Rakhila, M., Dhanalakshmi, M., Sajeev, R., Gad, A., Jayan, K., ... & UC, A. J. (2018). Feature optimization in high dimensional chemical space: statistical and data mining solutions. BMC research notes, 11(1), 1-7.
20. Dahms, S. O., Jiao, G. S., & Than, M. E. (2017). Structural studies revealed active site distortions of human furin by a small molecule inhibitor. ACS chemical biology, 12(5), 1211-1216.
21. Meanwell, N. A. Improving drug candidates by design: A focus on physicochemical properties as a means of improving compound disposition and safety. Chem. Res. Toxicol. 24, 1420–1456 (2011). https://doi.org/10.1021/tx200211v
22. Cheng, F., Desai, R. J., Handy, D. E., Wang, R., Schneeweiss, S., Barabási, A. L., & Loscalzo, J. (2018). Network-based approach to prediction and population-based validation of in silico drug repurposing. Nature communications, 9(1), 1-12.
23. Pandya, M., Jani, S., Dave, V., & Rawal, R. (2020). Nanoinformatics: An Emerging Trend in Cancer Therapeutics. In Nanobiotechnology (pp. 135-162). Apple Academic Press.
24. Lata, K. S., Kumar, S., Vaghasia, V., Sharma, P., Bhairappanvar, S. B., Soni, S., & Das, J. (2018). Exploring Leptospiral proteomes to identify potential candidates for vaccine design against Leptospirosis using an immunoinformatics approach. Scientific reports, 8(1), 1-15.
25. Khandia, R., Singhal, S., Kumar, U., Ansari, A., Tiwari, R., Dhama, K., ... & Singh, R. K. (2019). Analysis of Nipah virus codon usage and adaptation to hosts. Frontiers in microbiology, 10, 886.
26. Rakhila, M., Jinuraj, K. R., Dhanalakshmi, M., Reshmi, D., Manuel, A. T., & Jaleel, U.C (2019). A Decision Making Components In Cyclisation Of Mannose Derivatives–a Computational Approach. IJRPC 2018, 8(1), 217-231.
27. Schneider, G., & Wrede, P. (1998). Artificial neural networks for computer-based molecular design. Progress in biophysics and molecular biology, 70(3), 175-222.
28. Anighoro, A., Bajorath, J., & Rastelli, G. (2014). Polypharmacology: challenges and opportunities in drug discovery: miniperspective. Journal of medicinal chemistry, 57(19), 7874-7887.
29. Murray, L., Loftin, C. & Gwyneth, C. (1985) Elevated Activity. 65, 1318–1323
30. Thepen, T., Huhn, M., Melmer, G., Tur, M. K., & Barth, S. (2009). Fcγ receptor 1 (CD64), a target beyond cancer. Current pharmaceutical design, 15(23), 2712-2718.
31. Tang, X., Yan, L., Li, H., Du, L., Shi, Y., Huang, F., & Tang, H. (2019). Increased expression of phosphoenolpyruvate carboxykinase cytoplasmic isoform by hepatitis B virus X protein affects hepatitis B virus replication. Journal of medical virology, 91(2), 258-264.
32. Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., ... & Bavari, S. (2016). Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature, 531(7594), 381-385.
33. Li, Y., Cao, L., Li, G., Cong, F., Li, Y., Sun, J., ... & Zhang, X. (2021). Remdesivir metabolite GS-441524 effectively inhibits SARS-CoV-2 infection in mouse models. Journal of medicinal chemistry.
34. Behera, S. K., Vhora, N., Contractor, D., Shard, A., Kumar, D., Kalia, K., & Jain, A. (2021). Computational drug repurposing study elucidating simultaneous inhibition of entry and replication of novel corona virus by Grazoprevir. Scientific reports, 11(1), 1-11.
35. Bafna, K., White, K., Harish, B., Rosales, R., Ramelot, T. A., Acton, T. B., ... & Montelione, G. T. (2020). Hepatitis C Virus drugs simeprevir and grazoprevir synergize with remdesivir to suppress SARS-CoV-2 replication in Cell Culture. BioRxiv.
36. Nguyenla, X., Wehri, E., Van Dis, E., Biering, S., Yamashiro, L. H., Stroumza, J., ... & Schaletzky, J. (2020). Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells. BioRxiv.
37. Ni, X., Schröder, M., Olieric, V., Sharpe, M. E., Hernandez-Olmos, V., Proschak, E., ... & Chaikuad, A. (2021). Structural insights into plasticity and discovery of remdesivir metabolite GS-441524 binding in SARS-CoV-2 macrodomain. ACS medicinal chemistry letters, 12(4), 603-609.
38. Jung, L. S., Gund, T. M., & Narayan, M. (2020). Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment. The Protein Journal, 39(6), 619-630.
39. Humeniuk, R., Mathias, A., Kirby, B. J., Lutz, J. D., Cao, H., Osinusi, A., ... & German, P. (2021). Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Clinical pharmacokinetics, 1-15.
40. Yang, K. (2020). What do we know about remdesivir drug interactions?. Clinical and translational science, 13(5), 842.
41. Li, D., Hu, J., Li, D., Yang, W., Yin, S. F., & Qiu, R. (2021). Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. Topics in Current Chemistry, 379(1), 1-52.